Kennedy Jr. has downplayed the effectiveness of the long-used vaccine and instead promoted the development of new treatments ...

On an investor call Friday, analysts grilled the company over its apparent lack of transparency on the matter.

Sail Biomedicines is shrinking its crew for the second time this year. | Sail Biomedicines is shrinking its crew for the ...

Reeling from the deaths of two patients who took Duchenne muscular dystrophy gene therapy Elevidys, Sarepta is launching a ...

Heartflow is once again looking for a path to go public, with a filing for a Nasdaq IPO. | The former Fierce Medtech Fierce ...

The U.K. is establishing a new biosecurity center designed to improve research into potentially pandemic-causing pathogens ...

Intuitive Surgical is showing off the remote capability of its robots, with a transatlantic demonstration hosted by the ...

To secure the antibody, I-Mab is paying $1.8 million upfront to buy Bridge Health, to be followed by noncontingent quarterly ...

Abbott is doubling down on the structural heart space as it aims to gain ground in valve replacements following the recent ...

Sarepta Therapeutics is laying off 500 staffers, or 36% of its workforce, as part of a strategic restructuring aiming to save $400 million annually. | Sarepta Therapeutics has laid off 500 staffers, ...

The PD-1xVEGF dealmaking wave that has captivated Western pharma companies is now surging within China. | Sino Biopharm said ...

BioNTech is losing its chief strategy officer, with Ryan Richardson set to leave the company at the end of September to ...